I thought NP said "someone" mentioned a remdesivir and leronlimab combo trial for COVID on the webinar, but NP said he can't name pharmas(which wouldn't Gilead be the only one interested in that trial??). Either way he said CYDY wasn't interested until they at least finish their own trials.

Personally, I prefer Regeneron in a buyout. I could accept a 1 for 10 deal at todays REGN price. They already understand the monoclonal antibody angle because its what they do, and I don't know that I trust Gilead not to shelve this drug just to get it out of the way of their own current products.

All personal opinion, but I'd rather just concentrate on company progess. If we get something that comes up great, if CYDY goes it alone, fine. Just looking forward to launching the drug, and as the great PhD theologian Jacob Lelazari said "...and it will be launched!!"